MDxHealth Convenes Nov 19 Vote on Reverse Split of 1-for-5 to 1-for-30
MDXH is trading near its 52-week low of $0.159 (2.8% above the low) on light trading volume (0.2× avg).
Summary
MDxHealth has scheduled a November 19, 2026 shareholder vote on a reverse stock split ranging from 1-for-5 to 1-for-30, with the board choosing the final ratio within six months. The move comes with the stock near its 52-week low and follows a flat Q3 revenue pre-announcement.
Key Events · Corporate Governance and Compliance · MDXH
-
Reverse Split Put to Shareholder Vote
An extraordinary general meeting is set for November 19, 2026 to approve a share consolidation at a ratio between 1-for-5 and 1-for-30, with the board authorized to pick the final ratio within six months.
-
Approval Thresholds Set
The resolution needs 75% of votes validly cast and a 50% attendance quorum; if the quorum fails, a second meeting is scheduled for December 10, 2026.
-
Board Retains Cancellation Right
Directors may decline to implement, or suspend or cancel, the consolidation if they judge market circumstances unsatisfactory.
-
Fractional Shares to Be Sold
Shares that cannot be consolidated into whole new shares may be aggregated and sold, with proceeds distributed pro rata at no less than EUR 0.01 per existing share.
Analysis · MDXH · Industrial Applications And Services
Shareholders are being asked to approve a reverse stock split at a ratio the board can set anywhere from 1-for-5 to 1-for-30, with the final call left to directors for six months after the November 19, 2026 meeting. Why it matters: the stock trades at $0.1633, close to its 52-week low of $0.1588, so a consolidation is the standard route to lift the per-share price back above Nasdaq's minimum bid threshold and avoid a delisting process. The wide ratio band lets the board shrink the share count by as little as 80% or as much as about 97%, and it retains the right to walk away if market conditions don't cooperate. Approval needs 75% of votes cast and a 50% attendance quorum, with a second meeting on December 10, 2026 if the quorum fails. This lands against a rough backdrop: Q3 revenue pre-announced at roughly $22.7M was flat year over year and far below the $110-115M full-year target, and the September interim report disclosed a $10.4M Medicare recoupment claim. A reverse split fixes the share price optics, not the operating shortfall.
How filings like this one have moved
In the 30 days to Oct 31, 2026, 40% of the 995 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MDXH was trading at $0.16 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $15.6M. The 52-week trading range was $0.16 to $4.98. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.